Ignite Creation Date:
2024-05-06 @ 4:06 PM
Last Modification Date:
2024-10-26 @ 2:03 PM
Study NCT ID:
NCT04870164
Status:
TERMINATED
Last Update Posted:
2022-03-18
First Post:
2021-04-28
Brief Title:
Safety Tolerability and PK of Ensovibep MP0420 - a New Candidate With Potential for Treatment of COVID-19
Sponsor:
Molecular Partners AG
Organization:
Molecular Partners AG
Study Overview
Official Title:
A Phase 1 First-time-in-human Dose Ascending Study to Evaluate the Safety Tolerability and Pharmacokinetics of MP0420 a Novel Drug Candidate With Potential for Treatment of COVID-19 in Healthy Volunteers
Status:
TERMINATED
Status Verified Date:
2022-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Due to hypersensitivity observed in 3 subjects although no stopping rules were met the Sponsor decided to halt recruitment for further investigation After analysis of PK im administration was not required and recruitment stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate how ensovibep is distributed throughout the body the safety and the tolerability of ensovibep in healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2020-004365-39 | EUDRACT_NUMBER | None | None |